TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29893677

Group type: EXPERIMENTAL
Intervention: MiECC (priming volume 550mL)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: closeECC (priming volume 1250mL)
Number of subjects: 72

Group type: COMPARATOR
Intervention: openECC (priming volume 1250mL)
Number of subjects: 72
Study: 27128220

Group type: EXPERIMENTAL
Intervention: Playing Angry Birds on a hand-held computer
Number of subjects: 200

Group type: COMPARATOR
Intervention: Low-tech distraction by a nurse (singing, reading, blowing bubbles, playing with puppets)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study: 25310525

Group type: EXPERIMENTAL
Intervention: ECLA-F (face-to-face intervention)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: ECLA-T (telephone intervention)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 257
Study: 23639675

Group type: EXPERIMENTAL
Intervention: Garlic tablets
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 20604675

Group type: EXPERIMENTAL
Intervention: Systemic sclerosis patients
Number of subjects: 50

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 50
Study: 18156089

Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 6093

Group type: COMPARATOR
Intervention: Glycopeptides or β-lactams
Number of subjects: 6093
Study: 16759313

Group type: EXPERIMENTAL
Intervention: Intensive diet and exercise intervention
Number of subjects: 522

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 522
Study: 15748067

Group type: EXPERIMENTAL
Intervention: Home visits from trained personnel
Number of subjects: 480
Study: 10802992

Group type: EXPERIMENTAL
Intervention: Didactic course of the Army Reserve critical care nursing residency program
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (30 nurses)
Number of subjects: 27
Study: 8606262

Group type: EXPERIMENTAL
Intervention: Tirofiban (MK-383) administered in three sequential dose panels: bolus doses of 5, 10, and 10 microg/kg and continuous infusion doses of 0.05, 0.10, and 0.15 microg/kg per min for 16 to 24 hours
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo (heparin and aspirin only)
Number of subjects: 93
Study: 7933251

Group type: EXPERIMENTAL
Intervention: Critical carotid artery stenosis (80% to 99% diameter)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Noncritical carotid artery stenosis
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Critical carotid artery stenosis with APO
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Critical carotid artery stenosis
Number of subjects: 197
Study: 3279857

Group type: EXPERIMENTAL
Intervention: Ethanol ingestion (three doses)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ethanol ingestion
Number of subjects: 10
Study: 31599602

Group type: EXPERIMENTAL
Intervention: Boys Town In‐Home Family Services (IHFS) program for families
Number of subjects: 300

Group type: COMPARATOR
Intervention: Services as usual comparison group
Number of subjects: 300
Study: 29766413

Group type: EXPERIMENTAL
Intervention: Plaque disclosure with subsequent oral hygiene (tooth brushing with prior plaque disclosure)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional oral hygiene (tooth brushing)
Number of subjects: 20
Study: 28092416

Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine (360 ELISA units/dose) administered in three different schedules: (i) 0,1,2 months; (ii) 0,1,6 months; (iii) 0,1,12 months
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Group A (0,1,2 months)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Group B (0,1,6 months)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Group C (0,1,12 months)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Overall analysis
Number of subjects: 144
Study: 25403522

Group type: EXPERIMENTAL
Intervention: Perineal self‐acupressure plus standard treatment options
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard constipation treatment options
Number of subjects: 100
Study: 23298339

Group type: EXPERIMENTAL
Intervention: TDF/FTC
Number of subjects: 80

Group type: COMPARATOR
Intervention: ZDV/3TC
Number of subjects: 80
Study: 21639659

Group type: COMPARATOR
Intervention: Therapeutic Alliance video
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Experiential Acceptance video
Number of subjects: 105

Group type: COMPARATOR
Intervention: Alliance video
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control video
Number of subjects: 105
Study: 17412717

Group type: EXPERIMENTAL
Intervention: Tailored Internet-based intervention for self-care (LSE group)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Tailored Internet-based intervention for self-care (HSE group)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Non-targeted self-care areas (both groups)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Self-efficacy levels (both groups)
Number of subjects: 64
Study: 16842477

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 405

Group type: COMPARATOR
Intervention: Oral agents
Number of subjects: 405
Study: 14634491

Group type: EXPERIMENTAL
Intervention: Polyenylphosphatidylcholine
Number of subjects: 789

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 789
Study: 10617985

Group type: EXPERIMENTAL
Intervention: Algae-produced high-DHA triacylglycerol (170-260 mg/d)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-DHA eggs (170-260 mg/d)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-DHA, low-eicosapentaenoic acid marine oil (170-260 mg/d)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No supplementation (Control group)
Number of subjects: 24
Study: 7759034

Group type: COMPARATOR
Intervention: hydroxyethylsalicyclate gel
Number of subjects: 113
Study: 2182448

Group type: EXPERIMENTAL
Intervention: Low-dose oral verapamil treatment
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nonverapamil group
Number of subjects: 64
Study: 372063

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg twice daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 60
Study: 31657885

Group type: EXPERIMENTAL
Intervention: LabSafety application
Number of subjects: 316

Group type: COMPARATOR
Intervention: Traditional method
Number of subjects: 316

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 316
Study: 31157627

Group type: EXPERIMENTAL
Intervention: Transfusion of red blood cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transfusion practice guided by tissue oximeter and viscoelastic tests
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transfusion triggers for other blood products
Number of subjects: 0
Study: 28854266

Group type: EXPERIMENTAL
Intervention: On-pump CABG
Number of subjects: 2394

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 2394

Group type: COMPARATOR
Intervention: Combined analysis of on-pump and off-pump CABG
Number of subjects: 2394

Group type: COMPARATOR
Intervention: Logistic EuroSCORE
Number of subjects: 2394

Group type: COMPARATOR
Intervention: KCH score
Number of subjects: 2394

Group type: COMPARATOR
Intervention: Excluding female sex from risk models
Number of subjects: 2394
Study: 25664394

Group type: EXPERIMENTAL
Intervention: FLOX + cetuximab
Number of subjects: 453

Group type: COMPARATOR
Intervention: FLOX
Number of subjects: 453
Study: 23694982

Group type: EXPERIMENTAL
Intervention: Oral vinorelbine at 60 mg/m²
Number of subjects: 39

Group type: COMPARATOR
Intervention: Cisplatin at 40 mg/m²
Number of subjects: 39
Study: 21866183

Group type: EXPERIMENTAL
Intervention: DASH diet intervention
Number of subjects: 118

Group type: COMPARATOR
Intervention: Usual diet control (UC)
Number of subjects: 118
Study: 19843377

Group type: EXPERIMENTAL
Intervention: Antioxidants (vitamins E and C); n = 10
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (matching placebos); n = 10
Number of subjects: 20
Study: 16960440

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol (50 microg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15533340

Group type: EXPERIMENTAL
Intervention: Mid luteal phase biopsy (days 21-22)
Number of subjects: 847

Group type: EXPERIMENTAL
Intervention: Late luteal phase biopsy (days 26-27)
Number of subjects: 847
Study: 11422131

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) 800 microg/daily for 6 months
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 9491590

Group type: EXPERIMENTAL
Intervention: Secure attachment style
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ambivalent attachment style
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Avoidant attachment style
Number of subjects: 0
Study: 7906536

Group type: EXPERIMENTAL
Intervention: Vecuronium 20 micrograms kg‐1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Vecuronium 30 micrograms kg‐1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: British male average weight
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Australian male average weight
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 80
Study: 2566338

Group type: EXPERIMENTAL
Intervention: U.S. manufactured 50 mg film coated, waxed tablets
Number of subjects: 34

Group type: COMPARATOR
Intervention: European 50 mg film coated, waxed tablets
Number of subjects: 34

Group type: COMPARATOR
Intervention: Oral reference solution of almitrine bismesylate (0.5% w/v)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: U.S. manufactured tablets vs. European tablets
Number of subjects: 34
Study: 5060669

Group type: EXPERIMENTAL
Intervention: Rifampicin 600 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Isoniazid 600 mg
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Rifampicin and Isoniazid combination
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Isoniazid
Number of subjects: 2
Study: 30601823

Group type: COMPARATOR
Intervention: Standard of Care (SOC) with a clinic invitation letter
Number of subjects: 2349

Group type: EXPERIMENTAL
Intervention: HIVST + $3 financial incentive
Number of subjects: 2349

Group type: EXPERIMENTAL
Intervention: HIVST + $10 financial incentive
Number of subjects: 2349

Group type: EXPERIMENTAL
Intervention: HIVST alone
Number of subjects: 2349

Group type: EXPERIMENTAL
Intervention: HIVST + lottery (10% chance of $30)
Number of subjects: 2349

Group type: EXPERIMENTAL
Intervention: HIVST + phone reminder
Number of subjects: 2349
Study: 29320996

Group type: EXPERIMENTAL
Intervention: CCHP + HAP
Number of subjects: 945

Group type: COMPARATOR
Intervention: CCHP + HAP Delayed
Number of subjects: 945
Study: 25407258

Group type: EXPERIMENTAL
Intervention: Fluconazole 400 mg once daily for 8 days
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 23070022

Group type: EXPERIMENTAL
Intervention: Kudzu extract (250 mg isoflavones, t.i.d.)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 17
Study: 22150036

Group type: EXPERIMENTAL
Intervention: Norovirus VLP vaccine
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 19961457

Group type: EXPERIMENTAL
Intervention: Lateral condensation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Lateral condensation of ProTaper Gutta‐percha
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Single ProTaper Gutta‐percha
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Warm vertical condensation
Number of subjects: 60
Study: 16314870

Group type: COMPARATOR
Intervention: PICK1 gene association study
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: D-serine involvement
Number of subjects: 0
Study: 15212772

Group type: EXPERIMENTAL
Intervention: Community-based interventions including individually tailored newsletters, interpersonal activities, and community-wide events such as walk-a-thons.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Community-based interventions
Number of subjects: 12
Study: 10867093

Group type: COMPARATOR
Intervention: VVIR pacing
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: DDDR pacing
Number of subjects: 407
Study: 9351754

Group type: EXPERIMENTAL
Intervention: Topical bupivacaine
Number of subjects: 105

Group type: COMPARATOR
Intervention: Intramuscular ketorolac
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 8471652

Group type: EXPERIMENTAL
Intervention: 15.6% BCAA solution
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 45% BCAA solution
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard AA solution (control group)
Number of subjects: 35
Study: 4066178

Group type: EXPERIMENTAL
Intervention: Perceptual retraining
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional occupational therapy
Number of subjects: 0
Study: 30227258

Group type: EXPERIMENTAL
Intervention: UPD + aPDT
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: UPD + CLM
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: UPD + CLM + aPDT
Number of subjects: 72

Group type: COMPARATOR
Intervention: UPD
Number of subjects: 72

Group type: COMPARATOR
Intervention: UPD + PDT
Number of subjects: 72
Study: 26458517

Group type: EXPERIMENTAL
Intervention: Interfering force field B (treatment group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Force field A (control group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Electroencephalography (EEG) measurements (control group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Electroencephalography (EEG) measurements (treatment group)
Number of subjects: 24
Study: 24612288

Group type: EXPERIMENTAL
Intervention: Isotonic resistance exercise at 60% MVC against right lateral jaw movements
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study: 21349603

Group type: EXPERIMENTAL
Intervention: Diabetes Education (DE) and Physical Exercise (PE)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Physical Exercise (PE)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Diabetes Education (DE)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Individual consultations (Control group)
Number of subjects: 108
Study: 19323612

Group type: EXPERIMENTAL
Intervention: Besifloxacin ophthalmic suspension 0.6%
Number of subjects: 957

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 957
Study: 17869298

Group type: EXPERIMENTAL
Intervention: InterStim implantation
Number of subjects: 163
Study: 15547180

Group type: EXPERIMENTAL
Intervention: Paclitaxel-FAC
Number of subjects: 524

Group type: COMPARATOR
Intervention: FAC
Number of subjects: 524
Study: 11674909

Group type: EXPERIMENTAL
Intervention: Comprehensive Annotated Reminder Tool (CART)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CART
Number of subjects: 0
Study: 9040722

Group type: EXPERIMENTAL
Intervention: Cabergoline (0.25 to 4 mg/d)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Levodopa (100 to 600 mg/d)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Cabergoline with additional levodopa/carbidopa
Number of subjects: 208

Group type: COMPARATOR
Intervention: Levodopa with additional levodopa/carbidopa
Number of subjects: 208
Study: 7955181

Group type: EXPERIMENTAL
Intervention: Fish oil (8 g/d of omega-3 fatty acids, 10 capsules of 1.0 g each containing 80.6% ethyl esters of omega-3 fatty acids, providing 4.1 g EPA and 2.8 g DHA)
Number of subjects: 551

Group type: COMPARATOR
Intervention: Corn oil (equal amount of ethyl ester of corn oil)
Number of subjects: 551
Study: 2962799

Group type: EXPERIMENTAL
Intervention: Thymopentin (TP5) 50 mg administered subcutaneously 3 times weekly for 1 month
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 760924

Group type: EXPERIMENTAL
Intervention: Behaviour modification
Number of subjects: 81

Group type: COMPARATOR
Intervention: Absence of behaviour modification (Control)
Number of subjects: 81
Study: 30587408

Group type: EXPERIMENTAL
Intervention: comfilcon A
Number of subjects: 0

Group type: COMPARATOR
Intervention: lotrafilcon-B
Number of subjects: 0

Group type: COMPARATOR
Intervention: samfilcon-A
Number of subjects: 0

Group type: COMPARATOR
Intervention: filcom-V3
Number of subjects: 0
Study: 27421817

Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg once daily
Number of subjects: 765

Group type: EXPERIMENTAL
Intervention: Fexofenadine 60 mg twice daily
Number of subjects: 765

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 765
Study: 25885172

Group type: EXPERIMENTAL
Intervention: PF-04937319 100 mg
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Titrated glimepiride
Number of subjects: 639

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 639
Study: 24059475

Group type: EXPERIMENTAL
Intervention: State Mindfulness Scale (SMS) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 21346605

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (40 IU)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 19379618

Group type: EXPERIMENTAL
Intervention: CMC mesh packing
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: CMC gel packing
Number of subjects: 26

Group type: COMPARATOR
Intervention: No nasal packing
Number of subjects: 26
Study: 17581158

Group type: EXPERIMENTAL
Intervention: Amicus
Number of subjects: 22
Study: 12845454

Group type: EXPERIMENTAL
Intervention: Doppler-guided hemorrhoid artery ligation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Closed scissors hemorrhoidectomy
Number of subjects: 60
Study: 11805451

Group type: COMPARATOR
Intervention: Topical heat application before exercise in normal controls
Number of subjects: 16

Group type: COMPARATOR
Intervention: Topical heat application after exercise in normal controls
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ambient room temperature in subjects with myofascial pain
Number of subjects: 16

Group type: COMPARATOR
Intervention: Topical heat application in subjects with myofascial pain
Number of subjects: 16
Study: 10196552

Group type: EXPERIMENTAL
Intervention: Consistent displacement of visual target during saccadic eye movements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random displacement of visual target during saccadic eye movements
Number of subjects: 0
Study: 8156047

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.250 mg/ml
Number of subjects: 53

Group type: COMPARATOR
Intervention: Sufentanil 0.050 mg/ml
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 53

Group type: COMPARATOR
Intervention: Sufentanil
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 53
Study: 2963349

Group type: EXPERIMENTAL
Intervention: Physical therapist management
Number of subjects: 107

Group type: COMPARATOR
Intervention: Physician management
Number of subjects: 107
Study: 31934793

Group type: EXPERIMENTAL
Intervention: Low-dose group (LDG) - two Iyengar yoga sessions a week
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High-dose group (HDG) - three Iyengar yoga sessions a week
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Total cohort
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Participants with increased GABA levels at Scan-2
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Participants with no increase in GABA levels at Scan-2
Number of subjects: 15
Study: 31322602

Group type: EXPERIMENTAL
Intervention: Standard metal crowns (3M ESPE USA)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Filling materials (glass ionomer cements, compomers)
Number of subjects: 77
Study: 28138765

Group type: EXPERIMENTAL
Intervention: Carperitide (0.01 µg/kg/min)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 30
Study: 27012083

Group type: EXPERIMENTAL
Intervention: Surgical procedure (V basal osteotomy of the central metatarsals with elevation of the first metatarsal, dorsal osteotomy plus closing osteotomy, and elevation of the fifth metatarsal)
Number of subjects: 24
Study: 23278590

Group type: EXPERIMENTAL
Intervention: Eltrombopag 50 mg daily for up to 6 weeks (1 cycle) followed by up to 4 weeks off therapy
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Eltrombopag 50 mg daily
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Eltrombopag treatment
Number of subjects: 65
Study: 22047926

Group type: EXPERIMENTAL
Intervention: Bupivacaine plus fentanyl (1 mL of 50 μg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bupivacaine plus tramadol (1 mL of 50 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bupivacaine alone (30 mL of 0.25%)
Number of subjects: 60
Study: 18461103

Group type: EXPERIMENTAL
Intervention: Weight lifting combined with plyometric exercises for 6 weeks
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 37
Study: 17154377

Group type: EXPERIMENTAL
Intervention: IV anti-D
Number of subjects: 9

Group type: COMPARATOR
Intervention: IVIG
Number of subjects: 9
Study: 15790189

Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg per day for 2 years)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Tamoxifen (20 mg per day for 2 years)
Number of subjects: 20
Study: 11708233

Group type: EXPERIMENTAL
Intervention: Responding in Peaceful and Positive Ways (RIPP) program
Number of subjects: 626

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 626
Study: 9168368

Group type: COMPARATOR
Intervention: Hydration solution (5% dextrose)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Standard PN (25% dextrose, 5% amino acids)
Number of subjects: 258
Study: 7959860

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 0
Study: 3301915

Group type: EXPERIMENTAL
Intervention: Listerine antiseptic (LA) 2 or 4 times daily for 2 weeks
Number of subjects: 103

Group type: COMPARATOR
Intervention: Vehicle control (VC) twice daily for 2 weeks
Number of subjects: 103
Study: 31719170

Group type: EXPERIMENTAL
Intervention: Trichomonas vaginalis presence
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Trichomoniasis
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: Baseline trichomoniasis
Number of subjects: 647
Study: 30015066

Group type: EXPERIMENTAL
Intervention: Albiglutide 30 mg (potentially increasing to 50 mg) administered once weekly by subcutaneous injection
Number of subjects: 9463

Group type: COMPARATOR
Intervention: Matching placebo administered once weekly by subcutaneous injection
Number of subjects: 9463